Harpoon Therapeutics 将来の成長

Future 基準チェック /26

Harpoon Therapeutics利益と収益がそれぞれ年間10.6%と35.3%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に-220.2% 25.7%なると予測されています。

主要情報

10.6%

収益成長率

25.7%

EPS成長率

Biotechs 収益成長	28.4%
収益成長率	35.3%
将来の株主資本利益率	-220.2%
アナリストカバレッジ	Good
最終更新日	11 Mar 2024

今後の成長に関する最新情報

Recent updates

Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified

Jan 30

Harpoon Therapeutics, Inc. (NASDAQ:HARP) Looks Inexpensive After Falling 55% But Perhaps Not Attractive Enough

Oct 01

Analysts Just Made A Notable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts

Aug 14

Forecast: Analysts Think Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) Business Prospects Have Improved Drastically

May 28

Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation

Jul 30

Harpoon Therapeutics: A T-Cell Engager Platform And A Negative Enterprise Value Makes It A Candidate For My 'Bio Boom' Portfolio

Jul 07

Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?

Mar 08

We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate

Nov 30

Harpoon Therapeutics: A First Look

Sep 16

Harpoon shares slide after early-stage prostate cancer study data fails to impress

Jun 04

業績と収益の成長予測

NasdaqCM:HARP - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	47	-76	-67	-94	5
12/31/2025	23	-67	-54	-64	8
12/31/2024	21	-56	-33	-51	8
12/31/2023	38	-26	-16	-40	8
9/30/2023	37	-30	-69	-69	N/A
6/30/2023	47	-40	-77	-77	N/A
3/31/2023	35	-59	-84	-83	N/A
12/31/2022	32	-68	-90	-89	N/A
9/30/2022	32	-71	-88	-88	N/A
6/30/2022	23	-76	-84	-84	N/A
3/31/2022	21	-75	-129	-129	N/A
12/31/2021	24	-117	-122	-122	N/A
9/30/2021	27	-107	-121	-120	N/A
6/30/2021	26	-103	-114	-113	N/A
3/31/2021	23	-99	-10	-9	N/A
12/31/2020	17	-50	-9	-9	N/A
9/30/2020	12	-53	39	40	N/A
6/30/2020	10	-55	40	43	N/A
3/31/2020	8	-55	-11	-8	N/A
12/31/2019	6	-56	-6	-3	N/A
9/30/2019	5	-51	-46	-43	N/A
6/30/2019	4	-42	-41	-39	N/A
3/31/2019	4	-36	-33	-32	N/A
12/31/2018	5	-27	-28	-27	N/A
9/30/2018	4	-23	-9	-8	N/A
12/31/2017	1	-17	-1	2	N/A

アナリストによる今後の成長予測

収入対貯蓄率: HARP今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: HARP今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: HARP今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: HARPの収益 ( 35.3% ) US市場 ( 9% ) よりも速いペースで成長すると予測されています。

高い収益成長: HARPの収益 ( 35.3% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: HARP 3 年以内に赤字になると予測されています。

Harpoon Therapeutics 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus estimates of losses per share improve by 16%

Price target increased by 16% to US$16.33

Consensus EPS estimates upgraded to US$4.44 loss

Consensus EPS estimates fall by 52%

Price target decreased by 14% to US$45.83

Consensus estimates of losses per share improve by 10%

Recent updates

Harpoon Therapeutics Files Form 15

Harpoon Therapeutics, Inc.(NasdaqCM:HARP) dropped from NASDAQ Composite Index

Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified

Consensus estimates of losses per share improve by 16%

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Price target increased by 16% to US$16.33

Harpoon Therapeutics, Inc. Announces Board Changes

Harpoon Therapeutics, Inc. Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Shareholder dilution

Consensus EPS estimates upgraded to US$4.44 loss

Harpoon Therapeutics, Inc. announced that it expects to receive $100.162904 million in funding from a group of investors

New major risk - Share price stability

Harpoon Therapeutics, Inc. (NASDAQ:HARP) Looks Inexpensive After Falling 55% But Perhaps Not Attractive Enough

Harpoon Therapeutics Receives Non-Compliance Notice from Nasdaq

Harpoon Therapeutics, Inc. Announces Presentation of Interim Data for 2.15 to 12 mg Target Dose Cohorts from its Phase 1 Clinical Trial Evaluating Single-Agent HPN217 in Relapsed/Refractory Multiple Myeloma

Consensus EPS estimates fall by 52%

Price target decreased by 14% to US$45.83

Consensus estimates of losses per share improve by 10%

Forecast to breakeven in 2024

Consensus revenue estimates increase by 57%

Analysts Just Made A Notable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts

Price target increased by 11% to US$5.33

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Harpoon Therapeutics, Inc. Appoints Haibo Wang as Senior Vice President of Business Development

Insufficient new directors

Price target decreased by 9.8% to US$4.81

Harpoon Therapeutics, Inc. Announces Completion of Planned Patient Enrollment in Phase 1 Study of Hpn217 in Relapsed/Refractory Multiple Myeloma

Forecast: Analysts Think Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) Business Prospects Have Improved Drastically

Consensus EPS estimates upgraded to US$1.12 loss

Forecast to breakeven in 2024

Consensus EPS estimates fall by 20%, revenue upgraded

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 20% to US$5.43

Consensus revenue estimates fall by 45%

Insufficient new directors

Full year 2022 earnings: EPS and revenues miss analyst expectations

Harpoon Therapeutics (NASDAQ:HARP) Will Have To Spend Its Cash Wisely

Harpoon Therapeutics, Inc. Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma

Harpoon Therapeutics Receives a Letter from Nasdaq Regarding Minimum Closing Bid Price

Consensus revenue estimates increase by 28%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Harpoon Therapeutics, Inc. Appoints Luke Walker, M.D., as Chief Medical Officer

Harpoon Therapeutics appoints Luke Walker as CMO

Harpoon Therapeutics Appoints Lauren Silvernail to Board of Directors

Harpoon Therapeutics: A Well Undervalued Tri-Specific Oncology Player

Price target decreased to US$8.78

Price target decreased to US$10.67

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Harpoon Therapeutics, Inc. Announces Resignation of Georgia L. Erbez as Chief Financial Officer, Effective August 31, 2022

Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation

Harpoon Therapeutics: A T-Cell Engager Platform And A Negative Enterprise Value Makes It A Candidate For My 'Bio Boom' Portfolio

Harpoon Therapeutics, Inc. Announces Executive Appointments

Harpoon Therapeutics, Inc.(NasdaqGS:HARP) dropped from Russell 2000 Growth Index

Harpoon Therapeutics, Inc. Presents Interim Data from Ongoing Dose Escalation Portion of T Cell Engager HPN328 Clinical Trial

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Harpoon Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

Price target decreased to US$14.50

Harpoon Therapeutics, Inc. Presents Preclinical Data for TriTAC-XR Platform that Supports Potential for Improved Safety by Minimizing Cytokine Release Syndrome

Natalie Sacks to Leave Harpoon Therapeutics, Inc. as Chief Medical Officer, Effective June 1, 2022

Consensus forecasts updated

Price target decreased to US$23.00

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?

Harpoon Therapeutics Receives FDA Fast Track Designation for HPN217

Harpoon Therapeutics Receives FDA Fast Track Designation for HPN217